Actively Recruiting
Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers
Led by MoCA Clinic and Institute · Updated on 2025-07-01
500
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
M
MoCA Clinic and Institute
Lead Sponsor
C
C2N Diagnostics
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study evaluates a diagnostic screening solution for Alzheimer's disease (AD) using digital cognitive assessments and blood-based biomarkers. The aim is to reduce time-to-treatment for patients who may benefit from disease-modifying therapy (DMT). The study involves 500 patients referred to the MoCA Clinic in Montreal. Clinical stages will be assessed using digital tools from MoCA Test Inc. (MoCA Cognition), and biological stages via blood biomarkers. Data collected includes demographics, cognitive scores, health questionnaires, biomarker levels, and neurologist-determined eligibility for DMT. The study will result in an algorithm to support diagnostic triage and estimate the efficiency and equity of a fast-track diagnostic pathway. Exploratory endpoints include validation of self-administered digital tools, health-economic estimates, and predictors of cognitive decline.
CONDITIONS
Official Title
Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must be referred to the MoCA Clinic, including new patients and existing patients seen more than 1 year ago
- Have cognitive impairment or complaints about cognition
- Be able to understand the study purpose and risks and give informed consent
- Have a study partner who knows the participant well, can provide accurate information, be available by phone, and attend one in-person visit
- The study partner should be available for the entire duration of the study
You will not qualify if you...
- Have a known diagnosis other than Alzheimer's disease causing cognitive impairment (e.g., substance abuse, cerebrovascular disease, Lewy body dementia, fronto-temporal dementia, recent head trauma)
- Donated one unit of blood within 1 month before screening
- Unable to complete essential study components due to issues like severe visual impairment or kidney disease
- Currently enrolled in another Alzheimer's disease clinical trial at screening
- Other reasons deemed unsuitable by the Principal Investigator or MoCA Clinic staff
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MoCA Clinic and Institute
Greenfield Park, Quebec, Canada, J4V 2J2
Actively Recruiting
Research Team
J
Johanna Gruber, MSc
CONTACT
J
Joanna Krieger
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here